You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Early recognition of POEMS syndrome: what is the role of clinical neurophysiology?
  1. Kimiyoshi Arimura
  1. Okatsu Neurology and Rehabilitation Hospital, 3-95 Masagohonpachi, Kagoshima, Japan
  1. Correspondence to Dr Kimiyoshi Arimura, Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medicine, 8351 Sakuragaoka, Kagoshima 9.80852e+006, Japan; ari{at}m2.kufm.kagoshima-u.ac.jp

https://doi.org/10.1136/jnnp-2012-302477

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    POEMS syndrome (also known as Crow–Fukase syndrome) is a serious systemic disease characterised by polyneuropathy, anasarca, skin lesions and associated with ostoclastic bone lesions and with M-proteinemia. The diagnosis of POEMS syndrome is made robust by finding increased serum/plasma vascular endothelial growth factor (VEGF) in addition to the combination of the above mentioned characteristic manifestations.1 In fact, the recognition of POEMS syndrome has been enunciated by recent diagnostic guidelines from the western and Asian countries. From our end, a second nationwide survey of POEMS syndrome was conducted in Japan in 2004. The estimated number of affected individuals all over Japan was calculated …

    View Full Text

    Footnotes

    • Linked articles 301472, 301706.

    • Competing interests None.

    • Provenance and peer review Commissioned; externally peer reviewed.

    Linked Articles